Limits...
Retrospective public health impact of a quadrivalent influenza vaccine in the United States.

Crépey P, de Boer PT, Postma MJ, Pitman R - Influenza Other Respir Viruses (2015)

Bottom Line: Elderly (≥65 years) and young seniors (50-64 years) benefit most from QIV, with 21% and 18% reductions in B lineage cases.Reducing cross-protection to 50%, 30%, and 0% of the VE of the matched vaccine improves the relative benefit of QIV to 25%, 30%, and 34% less B lineage cases.Using a dynamic retrospective framework with real-life vaccine mismatch, our analysis shows that QIV routine vaccination in the United States has the potential to substantially reduce the number of influenza infections, even with relatively high estimates of TIV-induced cross-protection.

View Article: PubMed Central - PubMed

Affiliation: EHESP Rennes, Sorbonne Paris-cité, Paris, France.

No MeSH data available.


Related in: MedlinePlus

Vaccine efficacy sensitivity analysis. QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4549101&req=5

fig05: Vaccine efficacy sensitivity analysis. QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.

Mentions: Figure4 also shows that reducing the cross-protection estimate to 50%, 30%, and 0% of the matched VE improves the relative benefit of QIV to 25%, 30%, and 34% fewer B cases in the United States for all age groups. In Figure5, we show the impact of varying VE across all age groups by −20% to +20%. Increasing VE tends to linearly increase the relative benefits of QIV. In addition, in our model, VE and vaccine coverage play a mutually exchangeable role at the population level, which means that variations invaccination coverage by ±20% would display the same results. Hence, an increase in vaccination coverage would also raise QIV-relative benefits.


Retrospective public health impact of a quadrivalent influenza vaccine in the United States.

Crépey P, de Boer PT, Postma MJ, Pitman R - Influenza Other Respir Viruses (2015)

Vaccine efficacy sensitivity analysis. QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4549101&req=5

fig05: Vaccine efficacy sensitivity analysis. QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.
Mentions: Figure4 also shows that reducing the cross-protection estimate to 50%, 30%, and 0% of the matched VE improves the relative benefit of QIV to 25%, 30%, and 34% fewer B cases in the United States for all age groups. In Figure5, we show the impact of varying VE across all age groups by −20% to +20%. Increasing VE tends to linearly increase the relative benefits of QIV. In addition, in our model, VE and vaccine coverage play a mutually exchangeable role at the population level, which means that variations invaccination coverage by ±20% would display the same results. Hence, an increase in vaccination coverage would also raise QIV-relative benefits.

Bottom Line: Elderly (≥65 years) and young seniors (50-64 years) benefit most from QIV, with 21% and 18% reductions in B lineage cases.Reducing cross-protection to 50%, 30%, and 0% of the VE of the matched vaccine improves the relative benefit of QIV to 25%, 30%, and 34% less B lineage cases.Using a dynamic retrospective framework with real-life vaccine mismatch, our analysis shows that QIV routine vaccination in the United States has the potential to substantially reduce the number of influenza infections, even with relatively high estimates of TIV-induced cross-protection.

View Article: PubMed Central - PubMed

Affiliation: EHESP Rennes, Sorbonne Paris-cité, Paris, France.

No MeSH data available.


Related in: MedlinePlus